Search
Physician Survey Shows Lack of Understanding of the FDA’s Approval Process
Many physicians are unfamiliar with how the Food and Drug Administration’s (FDA) regulates new drugs and medical devices, and they may be under the impression that the data supporting these approvals are more rigorous than they are, according to a national survey of physicians conducted by researchers at UC San Francisco (UCSF).Radioligand Therapy Plus Pembrolizumab May Benefit Patients with Advanced Prostate Cancer
Immune checkpoint inhibitors have demonstrated limited efficacy in treating prostate cancer. Efforts to improve outcomes with combination therapies have mostly failed to demonstrate improvements compared to other types of cancer.Study Finds Significant Chemical Exposures in Women With Cancer
In a sign that exposure to certain endocrine-disrupting chemicals may be playing a role in cancers of the breast, ovary, skin and uterus, researchers have found that people who developed those cancers have significantly higher levels of these chemicals in their bodies.Inclusion of New Risk Factors Can Improve Prediction of Invasive Breast Cancer
UCSF researchers update Breast Cancer Surveillance Consortium model to account for BMI and other familial risk factors.New Keys to Cancer Care: How 2023 Findings Impact Treatment Decisions
These four collaborative talks from UCSF and John Muir Health specialists shine a light on recent study results that should inform treatment planning for patients with a variety of GI, breast, lung and blood cancers.UCSF Cancer Researcher Thomas Martin Receives $4.6 million CIRM Grant
UC San Francisco’s Thomas G. Martin, MD, a leading expert in blood cancers, has received a grant of nearly $4.6 million from the California Institute of Regenerative Medicine (CIRM) to produce a CAR T cell therapy for multiple myeloma, the second most common malignancy among blood cancers.Can Gene Expression Predict if a Brain Tumor Is Likely to Grow Back?
Screening tumors using this new approach could change the course of treatment for nearly 1 in 3 people with meningioma, the most common form of brain tumor diagnosed in 42,000 Americans each year.Improving Prediction of Advanced Breast Cancer Among Women of Different Races and Ethnicities
While regular screenings may decrease the chance of diagnosis of advanced breast cancer in some women and lead to a 20% reduction in breast cancer mortality, other women will be diagnosed with advanced breast cancer despite screening at regular intervals.UCSF Health’s Eric Small, MD, Elected ASCO President for 2025-2026 Term
The American Society of Clinical Oncology (ASCO) has elected Eric J. Small, MD, FASCO, to serve as its president for the term beginning in June 2025.Cancer Immunotherapy Toxicity Evaluation (CITE) Program
UCSF Health’s new Cancer Immunotherapy Toxicity Evaluation (CITE) Program is a valuable resource for both patient care and provider consults.A Novel Approach Towards a Vaccine for Relapsing Acute Myeloid Leukemia: Q&A with Dr. Karin Gaensler
There is a major clinical unmet need for effective and safe therapies to increase progression-free and overall survival in older individuals with leukemia whose prognosis is grim.UCSF Health Cancer Services Earns National Accreditation from the Commission on Cancer of the American College of Surgeons
The UCSF cancer program has been continuously accredited by the CoC since 1933, demonstrating its commitment to the best outcomes possible for its cancer patients.Scientists Discover a Deadly Brain Cancer’s Hidden Weakness
The difficult-to-treat brain cancer glioblastoma steals a person’s mental faculties as it spreads, yet the tumor’s insidious ability to infiltrate distant networks in the brain could also prove its undoing.UCSF Surgical Oncologists Providing New Treatment Options for Patients with Metastatic Gastrointestinal Cancers
UCSF Health’s surgical oncology team is a Bay Area leader in an innovative chemotherapy infusion pump used to treat patients with widely metastatic colorectal and bile duct cancers that have spread to the liver and are no longer considered operable.Can Lymph Nodes Boost the Success of Cancer Immunotherapy?
New data from a clinical trial show therapies may activate lymph nodes to produce tumor-tackling T cells.First-line Pembrolizumab Plus Chemotherapy May Benefit Patients with Advanced Biliary Tract Cancers
The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the phase III KEYNOTE-966 clinical trial.Cardio-Oncology & Immunology: Specialized Cardiovascular Care for Cancer Patients
Led by a multidisciplinary team of specialists and researchers, our program optimizes the cardiovascular health of cancer patients and cancer survivors.Patients With Detectable PSA After Radical Prostatectomy Have Good Long-Term Outcomes, UCSF Researchers Find
Patients with a detectable prostate-specific antigen (PSA) after radical prostatectomy (RP) may have excellent long-term outcomes, according to two retrospective studies conducted by UCSF researchers.UCSF Surgical Oncologists Present Clinical Findings at International Conference
The latest advances in surgical cancer care and research were showcased at the Society of Surgical Oncology’s (SSO) Annual Meeting, the International Conference on Surgical Cancer Care. The meeting was held in Boston, from March 22 – 25, 2023.Advances in Breast Cancer Care: Individualized Screening, Treatments and Follow-Up
Karen Goodwin, DO, covers everything from how to answer patients’ questions on mammogram frequency to how to counsel them on breast cancer prevention.Killing Pancreatic Cancer with T Cells that Turbocharge Themselves
Novel Immunotherapy Pumps Out Cancer-Killing Cytokines Only Inside the TumorBreast Cancer Risk Calculator Can Assess Risk of Advanced Breast Cancer
Upcoming Conference to Focus on Breast Density and Prediction of Advanced and Interval Breast Cancer RiskUCSF and I-SPY 2 Breast Cancer Researchers Develop Newly Redefined Breast Cancer Response Subtypes
Research scientists and statisticians from UC San Francisco have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients.Drug Turns Cancer Gene Into "Eat Me" Flag for Immune System
UCSF-led study shows promising pre-clinical results in killing cancer cells resistant to current KRAS-targeted treatments.